GENE ONLINE|News &
2022-09-12| Trials & Approvals
BMS’s Once-Daily Plaque Psoriasis Treatment, Sotyktu, Gains FDA Approval to Rival Otezla
With solid data from two sets of clinical trials, the FDA approved Bristol Myers Squibb’s Sotyktu as a once-daily oral medication to treat moderate to severe plaque psoriasis. A day after the approval announcement, BMS posted more data supporting the drug’s promise from a long-term clinical trial demonstrating Sotyktu’s efficacy for up to two years with continuous treatment for plaque psoriasis.
Potential New Standard for Orally Administered Plaque Psoriasis Treatment
Plaque psoriasis is a prevalent, immune-mediated condition characterized by raised, inflamed, and scaly patches of skin covered with a silvery-white buildup of dead skin that may be painful or itchy for the patient. Approximately 7.5 million Americans have psoriasis, and about 90% of those suffer from plaque psoriasis. Nearly a quarter of Americans with plaque psoriasis deal with moderate to severe manifestations of the condition.
It's free! Log in now to read
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
Redefining Early Stage Investments (RESI) 2023 conference series – RESI Boston
BIO International Convention (BIO 2023)
BIO Asia-Taiwan 2023
2023 Bio Asia Pacific
3rd INTERNATIONAL CONFERENCE ON NUTRITION AND HEALTHCARE